ADPT Adaptive Biotechnologies Corporation - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ADPT Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$16.04
Analyst Target
$20.86
+30.0%
Upside
52W High
$20.76
52W Low
$6.25
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$2.47B
P/E
N/A
ROE
-27.8%
Profit margin
-21.5%
Debt/Equity
0.93
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ADPT's Advanced Deterministic Scorecard reveals significant financial health concerns: a Piotroski F-Score of 1/9 indicates severe operational weakness, and the absence of an Altman Z-Score raises distress risk concerns. Despite strong revenue growth (51% YoY) and impressive earnings surprises (74.22% average), the company remains unprofitable with negative margins, ROE, and ROA. Insider selling totaling $9.3M over six months signals bearish sentiment, and the stock trades at a premium valuation (Price/Sales: 8.91, Price/Book: 11.27) without a Graham Number or intrinsic value anchor. Analysts' strong_buy consensus appears disconnected from fundamental deterioration.
Key Strengths
51.00% YoY revenue growth indicates robust top-line expansion
Consistently beats earnings estimates (3/4 in last 4 quarters)
Average earnings surprise of 74.22% reflects strong execution relative to expectations
High gross margin of 40.38% suggests pricing power and efficient production
Strong analyst consensus with a 'strong_buy' recommendation and $20.86 target price
Key Risks
Piotroski F-Score of 1/9 signals extreme financial distress and operational inefficiency
Negative profitability across all key metrics: ROE (-27.82%), ROA (-6.79%), and profit margin (-21.48%)
Insider selling of $9.3M in last 6 months indicates lack of confidence from leadership
No Graham Number or intrinsic value estimate, implying no defensive fair value anchor
Debt/Equity ratio of 0.93 and negative cash flow metrics suggest reliance on external financing
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
31
Weak
25
65
50
15
0
AI Verdict
Weak
Key drivers: Low Piotroski F-Score (1/9), Negative profitability and ROE, High insider selling, Premium valuation without intrinsic anchor, No Altman Z-Score (distress risk unassessed)
Confidence
88%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- High revenue growth (51% YoY)
- Strong gross margin (40.38%)
Watchpoints
- No Graham Number or intrinsic value
- Price/Sales of 8.91 is high for a loss-making company
- Price/Book of 11.27 reflects premium valuation without earnings support
Future
65/100
Ref Growth rates
Positives
- 51.00% YoY revenue growth
- 74.22% average earnings surprise in last 4 quarters
- Strong analyst target price ($20.86)
Watchpoints
- Forward P/E of -59.41 indicates no earnings visibility
- Negative ROIC and lack of free cash flow data
- High growth expectations not yet validated by profitability
Past
50/100
Ref Historical trends
Positives
- 3 out of last 4 quarters beat estimates
- Improving EPS trend (from -$0.45 to -$0.09)
Watchpoints
- Persistent losses over 25 quarters
- Negative ROE and ROA for years
- Historical earnings volatility and negative surprises
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 3.34 and quick ratio of 3.08 suggest strong liquidity
- Debt/Equity of 0.93 is moderate
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial distress
- No Altman Z-Score (risk of distress unquantified)
- Negative ROE and ROA indicate poor capital efficiency
- No free cash flow or operating cash flow data
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- 0/100 dividend strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$16.04
Analyst Target
$20.86
Upside/Downside
+30.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ADPT and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ADPT
Adaptive Biotechnologies Corporation
Primary
|
-75.0% | +84.8% | +88.3% | +23.0% | -11.1% | +1.7% |
|
ATEC
Alphatec Holdings, Inc.
Peer
|
+4.7% | +20.4% | +33.9% | +44.4% | -24.8% | -11.9% |
|
AAPG
Ascentage Pharma Group Internat
Peer
|
+37.0% | +37.0% | +38.0% | -47.1% | -15.9% | -2.9% |
|
BHC
Bausch Health Companies Inc.
Peer
|
-78.1% | -29.4% | -24.3% | -12.7% | -17.7% | -15.3% |
|
ADUS
Addus HomeCare Corporation
Peer
|
-6.3% | +8.5% | -1.5% | -1.1% | +3.0% | +7.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-59.41
PEG Ratio
N/A
P/B Ratio
11.27
P/S Ratio
8.91
EV/Revenue
8.87
EV/EBITDA
-63.08
Market Cap
$2.47B
Profitability
Profit margins and return metrics
Profit Margin
-21.48%
Operating Margin
-17.82%
Gross Margin
40.38%
ROE
-27.82%
ROA
-6.79%
Growth
Revenue and earnings growth rates
Revenue Growth
+51.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.93
Moderate
Current Ratio
3.34
Strong
Quick Ratio
3.08
Excellent
Cash/Share
$1.48
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-05
$-0.09
+50.8% surprise
2025-11-05
$0.06
+143.3% surprise
2025-08-05
$-0.17
+28.6% surprise
Healthcare Sector Comparison
Comparing ADPT against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Return on Equity (ROE)
-27.82%
This Stock
vs
-56.84%
Sector Avg
-51.1%
(Below Avg)
Profit Margin
-21.48%
This Stock
vs
-20.8%
Sector Avg
+3.3%
(Better)
Debt to Equity
0.93
This Stock
vs
2.68
Sector Avg
-65.1%
(Less Debt)
Revenue Growth
51.0%
This Stock
vs
61.93%
Sector Avg
-17.7%
(Slower)
Current Ratio
3.34
This Stock
vs
3.47
Sector Avg
-3.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ADPT
Adaptive Biotechnologies...
|
BEARISH | $2.47B | - | -27.8% | -21.5% | $16.04 | |
|
ATEC
Alphatec Holdings, Inc.
|
BEARISH | $2.32B | - | -540.4% | -21.3% | $15.62 | |
|
AAPG
Ascentage Pharma Group Internat
|
BEARISH | $2.23B | - | -159.6% | -296.8% | $23.82 | |
|
BHC
Bausch Health Companies Inc.
|
BEARISH | $2.19B | 6.79 | 563.2% | 3.6% | $5.91 | |
|
ADUS
Addus HomeCare Corporation
|
NEUTRAL | $2.1B | 24.11 | 8.6% | 6.4% | $113.8 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-04 | PISKEL KYLE | Chief Financial Officer | Sale | 2,145 | $39,597 |
| 2026-02-04 | PISKEL KYLE | Chief Financial Officer | Option Exercise | 2,145 | $26,040 |
| 2026-02-03 | ROBINS HARLAN S. | Officer | Sale | 42,788 | $799,105 |
| 2026-02-02 | ROBINS CHAD M | Chief Executive Officer | Sale | 124,998 | $2,304,963 |
| 2026-01-12 | PISKEL KYLE | Chief Financial Officer | Sale | 4,290 | $77,220 |
| 2026-01-12 | PISKEL KYLE | Chief Financial Officer | Option Exercise | 4,290 | $52,081 |
| 2026-01-12 | LO FRANCIS | Officer | Sale | 79,590 | $1,411,131 |
| 2026-01-12 | LO FRANCIS | Officer | Option Exercise | 79,590 | $614,022 |
| 2026-01-06 | ROBINS HARLAN S. | Officer | Sale | 10,000 | $164,400 |
| 2026-01-05 | ROBINS CHAD M | Chief Executive Officer | Sale | 124,998 | $1,948,719 |
| 2026-01-02 | LO FRANCIS | Officer | Sale | 3,125 | $50,250 |
| 2026-01-02 | LO FRANCIS | Officer | Option Exercise | 3,125 | $12,469 |
| 2025-12-22 | LO FRANCIS | Officer | Sale | 4,394 | $76,895 |
| 2025-12-22 | LO FRANCIS | Officer | Option Exercise | 4,394 | $31,530 |
| 2025-12-22 | LO FRANCIS | Officer | Sale | 4,394 | $76,895 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
7 analysts
JP Morgan
2026-02-06
Overweight
Overweight
BTIG
2026-02-06
Buy
Buy
Guggenheim
2026-01-26
Buy
Buy
Morgan Stanley
2025-11-11
Equal-Weight
Equal-Weight
JP Morgan
2025-11-06
Overweight
Overweight
BTIG
2025-11-06
Buy
Buy
BTIG
2025-10-22
Buy
Buy
Piper Sandler
2025-10-15
Overweight
Overweight
JP Morgan
2025-10-13
Overweight
Overweight
Guggenheim
2025-09-30
Buy
Past News Coverage
Recent headlines mentioning ADPT from our newsroom.
Newest → oldest
No matching news yet.